Last reviewed · How we verify
high dialysate calcium
high dialysate calcium is a Small molecule drug developed by Ege University. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | high dialysate calcium |
|---|---|
| Sponsor | Ege University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy
- The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD (PHASE2)
- The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
- Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration (NA)
- Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients (NA)
- Calcium Mass Balance and Dialytic Efficiency of a New cITRate-containing and Acetate-free Dialysis flUidS: CITRUS Study
- Adjusting Fluid Removal Based on Blood Volume in Hemodialysis: A Randomized Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- high dialysate calcium CI brief — competitive landscape report
- high dialysate calcium updates RSS · CI watch RSS
- Ege University portfolio CI
Frequently asked questions about high dialysate calcium
What is high dialysate calcium?
Who makes high dialysate calcium?
What development phase is high dialysate calcium in?
Related
- Manufacturer: Ege University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing